The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 28, 2025

Filed:

May. 04, 2021
Applicant:

Merck Sharp & Dohme Llc, Rahway, NJ (US);

Inventors:

Brandon D. Cash, Natick, MA (US);

Wenlang Fu, Madison, NJ (US);

George Madalin Giambasu, Natick, MA (US);

Andrew M. Haidle, Somerville, MA (US);

Brett A. Hopkins, Brownsburg, IN (US);

Matthew A. Larsen, Templeton, CA (US);

Charles A. Lesburg, Waban, MA (US);

Ping Liu, Westfield, NJ (US);

Meredeth A. Mcgowan, Boston, MA (US);

Qinglin Pu, Needham, MA (US);

Sulagna Sanyal, Belmont, MA (US);

Phieng Siliphaivanh, Newton, MA (US);

Catherine M. White, Canton, MA (US);

Xin Yan, Newton, MA (US);

Assignee:

Merck Sharp & Dohme LLC, Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/10 (2006.01); C07D 235/26 (2006.01); C07D 401/06 (2006.01); C07D 401/08 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/06 (2006.01); C07D 405/06 (2006.01); C07D 409/06 (2006.01); C07D 409/14 (2006.01); C07D 413/10 (2006.01); C07D 417/10 (2006.01); C07D 419/10 (2006.01); C07D 495/04 (2006.01);
U.S. Cl.
CPC ...
C07D 403/10 (2013.01); C07D 235/26 (2013.01); C07D 401/06 (2013.01); C07D 401/08 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/06 (2013.01); C07D 405/06 (2013.01); C07D 409/06 (2013.01); C07D 409/14 (2013.01); C07D 413/10 (2013.01); C07D 417/10 (2013.01); C07D 419/10 (2013.01); C07D 495/04 (2013.01);
Abstract

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.


Find Patent Forward Citations

Loading…